Session 1B | Treatments in Transition: Medication, Monitoring and the Future of AOD Care
Tracks
.
| Monday, November 10, 2025 |
| 11:00 AM - 12:00 PM |
| C2.2 & C2.3 |
Details
Chair: Kate Senior
Speaker
Prof Carla Treloar
Sci Prof
Csrh, Unsw
Professor Paul Dietze
Co_director, Disease Elimination Program
Burnet Institute
The relationship between opioid agonist therapy and cessation of injecting drug use: Evidence from a prospective cohort study of people who inject drugs
11:10 AM - 11:20 AMBiography
Professor Dietze is one of Australia's leading alcohol and other drug researchers. He has led the SuperMIX cohort study6 since its inception in 2008.
Prof Suzanne Nielsen
Professor And Deputy Director, Monash Addiction Research Centre
Monash University
Did the introduction of a prescription drug monitoring program in Victoria influence rates and characteristics of people seeing multiple prescribers for controlled medicines in primary care settings?
11:20 AM - 11:30 AMBiography
Professor Suzanne Nielsen (BPharm BPharmSc[Hons] PhD MPS) is the Deputy Director of the Monash Addiction Research Centre and an NHMRC Leadership Fellow. Her research focuses on reducing drug-related harms, improving access to care, and understanding the impact of drug policy.
A/Prof Christina Marel
Associate Professor
The University of Sydney
Is heroin dependence a “chronic long-term condition”?
11:30 AM - 11:40 AMBiography
Christina Marel is Program Lead of Treatment and Translation in Complex Populations at the Matilda Centre. Her research focuses on improving our understanding of, and responses to, mental and substance use disorders in complex populations; and developing evidence-based resources to support the translation of research into clinical practice.
Dr Krista Siefried
Clinical Research Lead, Senior Lecturer, Deputy Director
National Centre for Clinical Research on Emerging Drugs
Safety and feasibility of oral naltrexone and bupropion for methamphetamine use disorder: the NABU pilot study
11:40 AM - 11:45 AMBiography
Clinical Research Lead at NCCRED and Senior Lecturer at UNSW NDARC and SVHS Alcohol and Drug Service. Over 20 years clinical experience. Her research focuses on novel treatments for emerging drug use, shaping global clinical guidelines and impacting policy to improve outcomes in addiction medicine and public health.
Dr Liam Acheson
Postdoctoral Fellow
National Centre for Clinical Research on Emerging Drugs
Acceptability of oral naltrexone and bupropion for treatment of methamphetamine use disorder
11:45 AM - 11:50 AMBiography
Liam is a postdoctoral fellow at NCCRED and NDARC, UNSW. They are an early career researcher who's research focuses on interventions to address methamphetamine use disorder and withdrawal, including clinical trials of lisdexamfetamine, naltrexone-bupropion, ketamine, digital interventions. They are also interested in stigma, service delivery and sleep.
APSAD 2025
Session 1B Q&A
11:50 AM - 12:00 PMBiography
Chair
Katherine Senior
Addiction Medicine Specialist
DASSA
